The association of cardiac arrhythmias with chimeric antigen receptor T cell therapy in hospitalised patients: Insights from National Inpatient Sample

Abstract

Chimeric antigen receptor-T (CAR-T) cell therapy is a novel adoptive cellular therapy involving the use of CARs (recombinant fusion proteins) that activate T cells upon the recognition of specific antigens resulting in the killing of target cancer cells [1,2]. CD-19-specific CAR-T cell therapy has revolutionised the care of patients with refractory and relapsing haematological malignancies [3,4]. However, CAR-T cell therapy has significant cardiac adverse effects including cardiac arrhythmias, heart failure, and QT prolongation [5,6].